First-line lung cancer: can Keytruda be stopped?


Only one near-term event remains to determine whether Keytruda will face any kind of challenge in first-line NSCLC.

2018 started with the promise of a first-line lung cancer shakeout but it looks likely to end with Merck & Co’s Keytruda even more entrenched than before.

This report into the first-line NSCLC space discusses key upcoming trial readouts and regulatory decisions. Vantage puts into context the developments that over recent months have seen Keytruda consolidate its dominant position.


Download Report

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.